Skye公布Nimacimab联合司美格鲁肽Cbeyond二期a阶段扩展研究积极中期结果

美股速递02-02

Skye Bioscience Inc.（简称“Skye”）近日披露了其创新药物Nimacimab与司美格鲁肽（Semaglutide）联合用药的Cbeyond二期a阶段扩展研究的中期分析数据，结果显示疗效积极。

这项扩展研究旨在评估Nimacimab与司美格鲁肽联合治疗方案在特定患者群体中的长期安全性与有效性。中期数据表明，联合用药在关键疗效指标上表现出显著改善，且安全性和耐受性良好，未出现新的不良反应信号。

研究结果的积极进展为Nimacimab的后续临床开发提供了有力支持，也为相关疾病领域的治疗带来了新的潜在选择。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1167741515?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-02 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167741515","market":"us","top_or_hot":-1,"title":"Skye公布Nimacimab联合司美格鲁肽Cbeyond二期a阶段扩展研究积极中期结果","media":"美股速递","content":"<p>Skye Bioscience Inc.（简称“Skye”）近日披露了其创新药物Nimacimab与司美格鲁肽（Semaglutide）联合用药的Cbeyond二期a阶段扩展研究的中期分析数据，结果显示疗效积极。</p>\n<p>这项扩展研究旨在评估Nimacimab与司美格鲁肽联合治疗方案在特定患者群体中的长期安全性与有效性。中期数据表明，联合用药在关键疗效指标上表现出显著改善，且安全性和耐受性良好，未出现新的不良反应信号。</p>\n<p>研究结果的积极进展为Nimacimab的后续临床开发提供了有力支持，也为相关疾病领域的治疗带来了新的潜在选择。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Skye公布Nimacimab联合司美格鲁肽Cbeyond二期a阶段扩展研究积极中期结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSkye公布Nimacimab联合司美格鲁肽Cbeyond二期a阶段扩展研究积极中期结果\n</h2>\n\n<h4 class=\"meta\">\n\n2026-02-02 20:08 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Skye Bioscience Inc.（简称“Skye”）近日披露了其创新药物Nimacimab与司美格鲁肽（Semaglutide）联合用药的Cbeyond二期a阶段扩展研究的中期分析数据，结果显示疗效积极。\n这项扩展研究旨在评估Nimacimab与司美格鲁肽联合治疗方案在特定患者群体中的长期安全性与有效性。中期数据表明，联合用药在关键疗效指标上表现出显著改善，且安全性和耐受性良好，未出现新的...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1167741515","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167741515","pubTimestamp":1770034126,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Skye Bioscience Inc.（简称“Skye”）近日披露了其创新药物Nimacimab与司美格鲁肽（Semaglutide）联合用药的Cbeyond二期a阶段扩展研究的中期分析数据，结果显示疗效积极。\n这项扩展研究旨在评估Nimacimab与司美格鲁肽联合治疗方案在特定患者群体中的长期安全性与有效性。中期数据表明，联合用药在关键疗效指标上表现出显著改善，且安全性和耐受性良好，未出现新的不良反应信号。\n研究结果的积极进展为Nimacimab的后续临床开发提供了有力支持，也为相关疾病领域的治疗带来了新的潜在选择。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","SKYE":"Skye Bioscience Inc."},"translate_title":"Skye Announces Positive Interim Results of Nimacimab in Combination with Semaglutide Cbeyond Phase II Phase A Extension Study","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SKYE":1},"content_text":"Skye Bioscience Inc.（简称“Skye”）近日披露了其创新药物Nimacimab与司美格鲁肽（Semaglutide）联合用药的Cbeyond二期a阶段扩展研究的中期分析数据，结果显示疗效积极。\n这项扩展研究旨在评估Nimacimab与司美格鲁肽联合治疗方案在特定患者群体中的长期安全性与有效性。中期数据表明，联合用药在关键疗效指标上表现出显著改善，且安全性和耐受性良好，未出现新的不良反应信号。\n研究结果的积极进展为Nimacimab的后续临床开发提供了有力支持，也为相关疾病领域的治疗带来了新的潜在选择。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1167741515","isCrawlerRequest":true}